Role of Multi-modality Imaging in the Assessment of Chemotherapy Related Cardiac Dysfunction Among Cancer Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

190 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-02-01

Study Completion Date

2025-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The field of oncology has advanced remarkably. Some of the old and new emerging cancer therapies are associated with development of cardiovascular toxicities , which may have the potential to offset the gains in survival obtained with this cancer treatment advances. Much of the focus on cardiovascular toxicities has been in the early detection of myocardial damage and prediction of cancer therapeutics-related cardiac dysfunction (CTRCD). The main strategy for these patients is timely diagnosis and treatment of high-risk individual Cardiac dysfunction associated with cancer treatment is the main cause of mortality in cancer survivors. The mortality rate is recorded to be up to 60% in the first two years after therapy. The most commonly associated drugs with cardiotoxicity are anthracycline (AC) and monoclonal antibodies (such as trastuzumab). Other new agents, such as vascular endothelial growth factor (VEGF) inhibitors, immunotherapies, and proteasome inhibitors, can also cause cardiac dysfunction .

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PET/CT Quantitative Assessment of Myocardial Blood Flow Changes in Oncologic Patients Receiving Checkpoint Inhibitor Therapy

NCT04538950

Cancer

COMPLETED PHASE1/PHASE2

Early Detection of Imaging-derived Subclinical Cardiac Injuries

NCT03575650

Cardiovascular Diseases

RECRUITING

New Biomarkers in the Prediction of Chemotherapy-induced Cardiotoxicity.

NCT05992337

Cardiotoxicity Chemotherapy Effect Chemotherapy Induced Systolic Dysfunction

UNKNOWN

Early Predictor of Herceptin Cardio Toxicity in Breast Cancer Patients

NCT02062983

Breast Cancer

SUSPENDED

Optimising Screening for the Cardiotoxic Effects of Cancer Therapy

NCT06817044

Ventricular Dysfunction Cardiotoxicity Chemotherapeutic Toxicity

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

2D Speckle Tracking Echocardiography Breast Cancer Cardiac Magnetic Resonance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cancer patients receiving chemotherapeutic drugs

Cancer patients ≥ 18 years of age, and scheduled to receive chemotherapy will be included.

Two dimensions speckle tracking and three dimension echocardiography and cardiac magnetic resonance imaging

Intervention Type DEVICE

2D speckle tracking echo will be performed before chemotherapy and after mid-cycle and after completion of treatment.

3D echo and CMR will be performed before and after chemotherapy treatment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Two dimensions speckle tracking and three dimension echocardiography and cardiac magnetic resonance imaging

2D speckle tracking echo will be performed before chemotherapy and after mid-cycle and after completion of treatment.

3D echo and CMR will be performed before and after chemotherapy treatment.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Cancer patients ≥ 18 years of age, and scheduled to receive chemotherapy will be included.

Exclusion Criteria

* Contraindications to CMR (e.g.: patients with pacemakers, defibrillators or other implanted electronic devices).
* Life expectancy ≤ 12 months.
* Participating in another oncology clinical trial;
* Prior exposure to chemotherapy;
* History of active or prior cardiac disease (e.g., myocardial infarction, heart failure or base line left ventricular ejection fraction less than 55%).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No